
We’ve been told that hormone replacement therapy is most beneficial when started before age 60 or within 10 years of menopause. But where did that recommendation come from? And does it mean estrogen has no cardiovascular benefits after 60 or 70?
If you're a woman in your 60s who has been told she's missed the window for hormone replacement therapy, you may be wondering whether it's simply too late.
Or maybe you're in your 50s, already using estrogen, and wondering what happens when you turn 60. Do the benefits suddenly disappear? Should you stop taking it?
These are important questions, especially when we consider that cardiovascular disease is the leading cause of death among women.
The answer isn't as simple as an age cutoff.
The timing hypothesis helps explain when estrogen may have its most favorable effects on cardiovascular health. But it doesn't mean those effects magically disappear at 60, or that every woman over 60 faces the same risks.
To understand why, we need to look at where the research started, what subsequent studies have found, and what we still don't know.
First, what does estrogen actually do for your cardiovascular system?
Most women associate estrogen with menstrual cycles, hot flashes, and reproductive health. But estrogen receptors are found throughout the body, including in the heart and blood vessels.
Estrogen plays several important roles in cardiovascular physiology.
It helps support the production of nitric oxide, a molecule that allows blood vessels to relax and dilate. It influences cholesterol metabolism, endothelial function (the health of the inner lining of blood vessels), insulin sensitivity, and inflammatory signaling.
As estrogen levels decline during menopause, changes in cholesterol, body-fat distribution, insulin sensitivity, and vascular function can contribute to increasing cardiovascular risk.
This is one reason cardiovascular health deserves so much attention during the menopause transition.
But there's an important distinction.
Just because estrogen has beneficial effects on blood vessels doesn't automatically mean that replacing it will prevent heart attacks or strokes.
That question requires clinical research looking at actual cardiovascular events.
And that's where the timing hypothesis comes in.
Where did the timing hypothesis come from?
For decades, observational studies suggested that women using hormone replacement therapy had lower rates of cardiovascular disease than women who didn't use hormones.
This led many clinicians to believe estrogen replacement could help prevent heart disease.
Then came two major studies that changed the conversation.
The HERS study and the Women's Health Initiative
The Heart and Estrogen/progestin Replacement Study (HERS), published in 1998, evaluated oral estrogen combined with a synthetic progestin in women who already had coronary heart disease.
It found no overall reduction in coronary events and an early increase in risk after treatment began.
Then, in 2002, the first major hormone therapy results from the Women's Health Initiative (WHI) were published.
The WHI hormone trials enrolled more than 27,000 women between ages 50 and 79, with an average age of approximately 63.
The researchers evaluated two specific treatment regimens:
- Oral conjugated equine estrogens (CEE) combined with medroxyprogesterone acetate (MPA) in women with a uterus.
- Oral CEE alone in women who had undergone hysterectomy.
The initial results, particularly from the combined therapy trial, raised concerns about cardiovascular events and other risks.
Hormone therapy use declined dramatically.
But there was a critical detail that became increasingly important as researchers continued analyzing the data.
Many participants were considerably older than the women who typically begin hormone therapy for menopausal symptoms.
They were also using specific oral hormone preparations, not the full range of treatments available today.
When researchers examined outcomes by age and time since menopause, a more complicated picture began to emerge.
What the WHI actually showed about younger women
In the estrogen-only trial, women who began treatment between ages 50 and 59 had lower observed rates of certain coronary events compared with women receiving placebo.
For coronary heart disease, the estimated hazard ratio was 0.60, suggesting a possible 40% relative reduction. However, the confidence interval included the possibility of no benefit, so this result was not statistically definitive.
The pattern was less favorable in older participants.
Importantly, the estrogen-plus-progestin trial did not demonstrate the same coronary benefit in younger women.
This distinction matters because estrogen alone and estrogen combined with a particular progestin are not interchangeable treatments.
Researchers began exploring whether estrogen's cardiovascular effects depended not only on which hormones were used, but also on when treatment started.
That became known as the timing hypothesis.
What is the timing hypothesis?
The timing hypothesis proposes that estrogen's effects on the cardiovascular system depend partly on the condition of the arteries when treatment begins.
Imagine two women.
One is 52, recently menopausal, with relatively healthy blood vessels and little evidence of atherosclerosis.
The other is 70, has been postmenopausal for 20 years, and has more established plaque within her arteries.
Both women have low estrogen levels.
But their cardiovascular systems are not necessarily going to respond to estrogen in the same way.
In earlier stages of atherosclerosis, estrogen may support endothelial function and slow certain processes involved in plaque development.
Once more advanced plaque is present, estrogen may no longer produce the same protective effects. Depending on the formulation and underlying vascular disease, treatment could potentially increase the risk of thrombotic complications.
Researchers have proposed several mechanisms involving vascular inflammation, changes in estrogen receptor signaling, and the condition of existing plaque.
These mechanisms remain under investigation.
The central idea is that the health of the arteries may be just as important as a woman's chronological age.
What research supports the timing hypothesis?
Several studies have helped us understand the relationship between estrogen, timing, and cardiovascular outcomes.
The ELITE trial: Why timing matters
The Early versus Late Intervention Trial with Estradiol (ELITE), published in 2016, was designed specifically to investigate the timing hypothesis.
Researchers studied women who were either less than six years past menopause or at least 10 years past menopause.
Participants received oral estradiol or placebo, with progesterone added when needed.
Over approximately five years, researchers measured changes in carotid artery intima-media thickness, a marker of arterial wall thickening.
The results were interesting.
Women who started estradiol closer to menopause experienced significantly slower progression of carotid artery thickening.
Women who started treatment more than 10 years after menopause did not experience that same benefit.
This provided important support for the timing hypothesis.
However, the study measured a marker of atherosclerosis, not a reduction in heart attacks or cardiovascular deaths.
Other trials add important context
The Danish Osteoporosis Prevention Study followed women who began hormone therapy relatively close to menopause and found fewer deaths, heart attacks, or heart-failure events in the treatment group.
Those results were encouraging, although the study had limitations, including its open-label design and relatively small number of cardiovascular events.
The Kronos Early Estrogen Prevention Study (KEEPS) evaluated oral estrogen and transdermal estradiol in recently menopausal women.
Unlike ELITE, KEEPS did not demonstrate a significant reduction in carotid artery thickening over four years.
A 2015 Cochrane review also found that women starting hormone therapy within 10 years of menopause had lower mortality and fewer coronary events in subgroup analyses. However, the overall trial evidence did not establish hormone therapy as an effective cardiovascular prevention strategy, and oral regimens were associated with increased blood clot risk.
Taken together, these studies suggest that earlier initiation may offer cardiovascular advantages, but they do not conclusively establish hormone therapy as a way to prevent heart attacks in every woman.
So, does estrogen stop being beneficial at age 60?
No. There's no evidence that estrogen's biological effects suddenly stop on a woman's 60th birthday.
The commonly cited recommendation is to consider hormone therapy most favorably in healthy women who are younger than 60 or within 10 years of menopause onset.
Notice the word or.
A woman who reaches menopause at 55 and is considering hormone therapy at 62 is seven years past menopause.
Another woman who reaches menopause at 45 and is considering treatment at 62 is 17 years past menopause.
Both women are the same age, but they have different histories of estrogen exposure and potentially very different cardiovascular risk profiles.
The 10-year guideline is also a research-based threshold, not a biological switch that flips after exactly one decade.
That doesn't mean starting at 62 carries the same risks as starting at 52. Cardiovascular risk generally increases with age, and both age and time since menopause deserve consideration.
But it does mean that age alone cannot tell us everything we need to know.
What about starting estrogen at 70?
This is where the evidence becomes more cautionary.
A 2025 secondary analysis of the WHI trials examined cardiovascular outcomes in women who reported moderate or severe vasomotor symptoms.
Among women ages 50–59, the oral hormone regimens reduced symptoms without a statistically significant increase in atherosclerotic cardiovascular events.
Among women ages 60–69, the results were less certain.
In women ages 70–79 with vasomotor symptoms, both oral regimens were associated with significantly increased cardiovascular event risk.
The estimated hazard ratios were 1.95 for estrogen alone and 3.22 for estrogen combined with MPA.
These estimates came from relatively small subgroups of symptomatic older women, so they require careful interpretation.
And they don't answer every question about the safety of lower-dose transdermal estradiol.
But they do give us a reason to be more cautious about initiating systemic hormone therapy for the first time at 70.
A 2026 observational study involving more than 83,000 women also identified greater cardiovascular risk among women initiating hormone therapy at age 65 or older, although researchers could not adequately distinguish the effects of different formulations, doses, or routes of administration.
The evidence does not support beginning estrogen at 70 specifically to prevent cardiovascular disease.
It also doesn't prove that every woman beginning treatment at 70 will experience harm.
For women with persistent, significantly bothersome menopausal symptoms, an individualized discussion may still be appropriate.
The potential benefits must be weighed carefully against cardiovascular, clotting, stroke, breast cancer, and other relevant risks.
But what if you've been taking estrogen for years and are now 60 or 70?
This is a completely different question.
Starting hormone therapy at 70 is not the same as continuing treatment that began at 50.
The Menopause Society has specifically stated that hormone therapy does not need to be routinely discontinued at age 60 or 65.
Women who continue to benefit from treatment may be candidates for ongoing therapy, provided their individual risks and benefits are reassessed regularly.
That evaluation should include their current health, medical history, treatment formulation, dose, and reasons for continuing.
We still need better long-term clinical trials to understand the cardiovascular effects of continuing treatment for decades.
But there is no evidence-based rule requiring every woman to stop estrogen simply because she reaches a particular birthday.
Does the type of estrogen make a difference?
Absolutely. And this is one of the most important limitations when applying older research to modern treatment decisions.
Most of the landmark cardiovascular outcome trials involved oral conjugated equine estrogens, either alone or combined with medroxyprogesterone acetate.
Today, menopausal hormone therapy also includes transdermal estradiol delivered through patches, gels, and creams.
Transdermal estrogen enters the bloodstream through the skin, avoiding the initial passage through the liver that occurs with oral estrogen.
This matters because oral estrogen influences the production of certain clotting factors and other proteins involved in cardiovascular risk.
Observational studies generally find a lower risk of venous thromboembolism with transdermal estrogen compared with oral estrogen.
Micronized progesterone also appears to have a more favorable thrombotic profile than some synthetic progestins, although definitive cardiovascular outcome comparisons are limited.
However, there's an important limitation.
We don't yet have large randomized trials demonstrating that transdermal estradiol started after 60 or 70 prevents heart attacks or cardiovascular death.
A formulation that appears safer for blood clotting does not automatically provide proven protection from coronary artery disease.
That distinction is important when making evidence-based treatment decisions.
What does the newest research tell us?
Research is increasingly moving toward individualized cardiovascular risk assessment rather than relying exclusively on age.
A 2026 WHI secondary analysis published in Obstetrics & Gynecology examined how a woman's cardiovascular risk factors influenced her response to oral hormone therapy.
The researchers found that women with less favorable cholesterol profiles were more likely to experience increased coronary risk with certain oral hormone regimens.
For example, among women using CEE plus MPA, higher untreated LDL cholesterol was associated with greater coronary risk.
These findings were seen across age groups.
This doesn't establish that women with healthy cholesterol can safely use any hormone regimen, but it adds another important piece of information.
Your cardiovascular health at the time treatment begins matters.
A separate 2026 joint position paper from the International Federation of Gynecology and Obstetrics and the World Heart Federation emphasizes individualized evaluation, particularly for women with cardiovascular risk factors.
It also acknowledges that selected women with established ischemic heart disease may be considered for hormone therapy for symptom relief under careful specialist management.
This is not a recommendation to prescribe hormones to treat or prevent coronary disease.
Rather, it reflects a growing recognition that treatment decisions require more than a simple age cutoff.
What should we actually be evaluating before starting estrogen?
When I'm evaluating a woman for hormone replacement therapy, I want to understand more than her age or how many years it's been since her last period.
We need to look at her overall cardiovascular health.
That includes blood pressure, cholesterol and other lipid markers, diabetes and metabolic health, smoking history, family history, previous cardiovascular events, and other risk factors.
A history of conditions such as preeclampsia, gestational diabetes, or premature menopause can also influence cardiovascular risk.
For selected women, particularly when their cardiovascular risk is uncertain, coronary artery calcium scoring may provide additional information about existing calcified plaque.
A calcium score of zero can be reassuring in the appropriate setting, but it does not rule out all cardiovascular disease or guarantee that hormone therapy is risk-free.
And no matter how favorable the hormone therapy decision may be, estrogen does not replace established cardiovascular prevention strategies such as managing blood pressure, treating elevated cholesterol when indicated, maintaining physical activity, and addressing metabolic risk.
So, is there cardiovascular benefit from estrogen after 60?
Here's how I interpret the evidence.
Estrogen continues to interact with blood vessels, metabolism, and cardiovascular physiology throughout life.
There is no established age when all of those biological effects disappear.
But whether starting systemic estrogen after 60 actually reduces a woman's risk of a future heart attack or cardiovascular death is a different question.
We do not currently have convincing clinical trial evidence that initiating hormone therapy after 60 provides that protection.
And as women age, the likelihood of underlying atherosclerosis and other cardiovascular risk factors increases. That can change the balance between potential benefits and harms.
The strongest evidence for favorable cardiovascular effects is in healthier women who begin treatment closer to menopause, although even in that group, professional guidelines differ in how strongly they interpret the evidence for prevention.
The International Menopause Society's 2026 recommendations acknowledge potential coronary and mortality benefits when estrogen is initiated early in healthy women.
At the same time, major organizations do not recommend starting systemic hormone therapy solely to prevent cardiovascular disease.
These positions aren't necessarily contradictory.
One recognizes that cardiovascular benefits may influence an individualized treatment discussion.
The other recognizes that the evidence is not strong or consistent enough to use hormone therapy as a stand-alone heart disease prevention treatment.
The bottom line: Your age matters, but it's not the whole story
I don't believe women should be reduced to a number when making decisions about their health.
A woman at 62 who has significant menopausal symptoms, relatively recent menopause, and favorable cardiovascular health deserves a thoughtful evaluation.
A woman at 70 who has been successfully using estrogen for 15 years deserves a different discussion from someone wanting to begin treatment for the first time at 70.
And a woman in her early 50s deserves to understand both the potential benefits of hormone therapy and the limits of what the research can promise.
The timing hypothesis gives us valuable information about when estrogen may have its most favorable cardiovascular effects.
But it is a framework for clinical decision-making, not an expiration date.
The question shouldn't simply be, "Am I too old for estrogen?"
It should be, "Given my symptoms, cardiovascular health, medical history, and treatment options, what makes the most sense for me?"
That's the conversation women deserve.
At Midlifesy, we use comprehensive health assessments to understand what's happening in your body and create a personalized roadmap, including hormone replacement therapy when appropriate.
Explore the Clarity Consult™ at Midlifesy to begin understanding your options.
This article is for educational purposes and is not a substitute for individualized medical advice. Hormone therapy decisions should be made with a qualified healthcare professional after reviewing personal risks, potential benefits, and treatment alternatives.
